Egetis Therapeutics

Board/Management Information • May 26, 2020

PRESS RELEASE PledPharma AB

CFO Yilmaz Mahshid leaves PledPharma

Stockholm, May 26, 2020. PledPharma AB (STO: PLED) today announced that its CFO Yilmaz Mahshid has decided to leave the company and take on the position as CEO of Medivir. He will stay with PledPharma until the autumn. The process to recruit his successor has been initiated.

"I have worked closely with Yilmaz during an intense period for the company, and I am very grateful for his commitment and professionalism. I wish him the best of luck with his future commitments", said Nicklas Westerholm, CEO, PledPharma.

For further information, please contact: Nicklas Westerholm, CEO Tel. +46 (0)73 354 20 62 nicklas.westerholm@pledpharma.se

The information was submitted for publication, through the agency of the contact persons set out above, at 2020-05-26, 08:30 CET.

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's project PledOx® is a first in class drug candidate and is being developed to prevent nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate Aladote® is a first in class drug candidate and is being developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed, and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/